Systems, methods, and apparatus are disclosed for determining quantitative hormone and chemical analyte results from qualitative test results. An image is taken of an ovulation test device. The image is analyzed to identify a darkness intensity ratio (T/C ratio) between a darkness value of a test-line to a darkness value of a control-line. Additionally, a quantitative substance level may be determined using the T/C ratio, by identifying the type of test device and referencing a data structure that relates quantitative substance levels to T/C ratios for the identified type of test device.

Various aspects of the system and methods described herein rely upon the operation of lateral flow assays specially configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from the lateral flow assays are optionally interpreted in association with an application operating upon a mobile device or a system for the collection, interpretation and storage of results. The interpretations are useful in accordance with facilitating diagnoses and treatments associated with medical conditions related to the generated interpretations of the lateral flow assays.

Various aspects of the system and methods described herein rely upon the operation of lateral flow assays specially configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from the lateral flow assays are optionally interpreted in association with an application operating upon a mobile device or a system for the collection, interpretation and storage of results. The interpretations are useful in accordance with facilitating diagnoses and treatments associated with medical conditions related to the generated interpretations of the lateral flow assays.

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

The present invention provides compositions and methods that provide a high degree of sensitivity and a high degree of specificity for the non-invasive assessment of endometriosis in women having a variety of endometriosis types (e.g., endometriosis, endometriotic cysts, endometrioma, or another benign condition of the endometrium) and at a variety of disease states (e.g., early and late stage).

The present invention provides compositions and methods that provide a high degree of sensitivity and a high degree of specificity for the non-invasive assessment of endometriosis in women having a variety of endometriosis types (e.g., endometriosis, endometriotic cysts, endometrioma, or another benign condition of the endometrium) and at a variety of disease states (e.g., early and late stage).

The present invention relates to a system and methods for evaluating and tracking the operation of the menstrual cycle and treating undesirable trends associated with the menstrual cycle. Various aspects of the system and methods described herein rely upon the operation of diagnostic tests specially configured to evaluate a bodily fluid for the presence or absence of hormones or analytes, and more specifically configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from one or more diagnostic tests are interpreted in accordance with the teachings of the system. The interpretations are useful in accordance with facilitating treatments associated with medical conditions correlated to the generated interpretations, optionally delivered during a consultation with a medical provider during a telemedicine consultation, the treatments optionally comprising dietary changes incorporating the consumption of certain seeds to mitigate hormonal imbalances.

The present invention relates to a system and methods for evaluating and tracking the operation of the menstrual cycle and treating undesirable trends associated with the menstrual cycle. Various aspects of the system and methods described herein rely upon the operation of diagnostic tests specially configured to evaluate a bodily fluid for the presence or absence of hormones or analytes, and more specifically configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from one or more diagnostic tests are interpreted in accordance with the teachings of the system. The interpretations are useful in accordance with facilitating treatments associated with medical conditions correlated to the generated interpretations, optionally delivered during a consultation with a medical provider during a telemedicine consultation, the treatments optionally comprising dietary changes incorporating the consumption of certain seeds to mitigate hormonal imbalances.

The present disclosure relates to water dispersible or soluble diagnostic assay methods, devices, kits, and methods of manufacture.